Multiple sclerosis

Annals of Internal Medicine

Volumn 160, Issue 7, 2014, Pages ITC4-

  Harrison, Daniel M ^a   Cotton, Deborah ^a   Rao, Jaya K ^a   Taichman, Darren ^a   Williams, Sankey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; TERIFLUNOMIDE;

BLINDNESS; DISEASE COURSE; EVOKED RESPONSE; EYE EXAMINATION; EYE MOVEMENT; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LUMBAR PUNCTURE; MEDICAL EDUCATION; MEDICAL HISTORY; MEDICAL SPECIALIST; MULTIPLE SCLEROSIS; MUSCLE TONE; MYELITIS; NEUROLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PHENOTYPE; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RETINAL THICKNESS; REVIEW; RISK FACTOR; RISK REDUCTION; VISUAL FIELD; PATIENT EDUCATION;

MULTIPLE SCLEROSIS; PATIENT EDUCATION AS TOPIC;

EID: 84902109830     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-160-7-201404010-01004     Document Type: Review

References (45)

1. Niedziela N, Adamczyk-Sowa M, Pierzchala K. Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review. Int J Neurosci. 2013. [Epub ahead of print] [PMID: 23998938]
2. Islam T, Gauderman WJ, Cozen W, Hamilton AS, Burnett ME, Mack TM. Differential twin concordance for multiple sclerosis by latitude of birthplace. Ann Neurol. 2006;60:56-64. [PMID: 16685699]
3. Patsopoulos NA, Barcellos L F, Hintzen RQ, Schaefer C, van Duijn CM, Noble JA, et al; IMSGC. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet. 2013;9:e1003926. [PMID: 24278027]
4. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, et al; International Multiple Sclerosis Genetics Consortium (IMSGC). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353-60. [PMID: 24076602]
5. van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor B V, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ. 2003;327:316. [PMID: 12907484]
6. Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM; NeuroproMiSe EBV Working Group. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue-report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain. 2011;134:2772-86. [PMID: 21846731]
7. O'Riordan JI, Thompson AJ, Kingsley D P, MacManus DG, Kendall BE, Rudge P, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 1998;121 (Pt 3):495-503. [PMID: 9549525]
8. Weinshenker BG, Bass B, Rice G P, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112 (Pt 1):133-46. [PMID: 2917275]
9. Kremenchutzky M, Rice G P, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129:584-94. [PMID: 16401620]
10. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302. [PMID: 21387374]
11. Rocca MA, Messina R, Filippi M. Multiple sclerosis imaging: recent advances. J Neurol. 2013;260:929-35. [PMID: 23263475]
12. Stangel M, Fredrikson S, Meinl E, Petzold A, Stüve O, Tumani H. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol. 2013;9:267-76. [PMID: 23528543]
13. Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:1720-5. [PMID: 10802774]
14. Parisi V, Manni G, Spadaro M, Colacino G, Restuccia R, Marchi S, et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci. 1999;40:2520-7. [PMID: 10509645]
15. Garcia-Martin E, Pablo LE, Herrero R, Satue M, Polo V, Larrosa JM, et al. Diagnostic ability of a linear discriminant function for spectraldomain optical coherence tomography in patients with multiple sclerosis. Ophthalmology. 2012;119:1705-11. [PMID: 22480742]
16. Langer-Gould AM, Anderson WE, Armstrong MJ, Cohen AB, Eccher MA, Iverson DJ, et al. The American Academy of Neurology's top five choosing wisely recommendations. Neurology. 2013;81:1004-11. [PMID: 23430685]
17. Kappos L, Freedman MS, Polman CH, Edan G, Hartung H P, Miller DH, et al; BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8:987-97. [PMID: 19748319]
18. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, doubleblind, placebo-controlled trial. Lancet. 2009;374:1503-11. [PMID: 19815268]
19. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for ex-acerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler. 1995;1:118-35. [PMID: 9345462]
20. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:655-61. [PMID: 8469318]
21. Flechter S, Vardi J, Pollak L, Rabey JM. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci. 2002;197:51-5. [PMID: 11997066]
22. Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, et al; CombiRx Investigators. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73:327-40. [PMID: 23424159]
23. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910. [PMID: 16510744]
24. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natal-izumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870-80. [PMID: 22591293]
25. Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, et al. A second-generation ELISA (STRATIFY JCVE DxSelectE) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57:141-6. [PMID: 23465394]
26. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362: 387-401. [PMID: 20089952]
27. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson T P, et al; TEM-SO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293-303. [PMID: 21991951]
28. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-107. [PMID: 22992073]
29. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence Report: The efficacy and safety of mitoxantrone (No-vantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74:1463-70. [PMID: 20439849]
30. Hauser SL, Johnston SC. Multiple sclerosis drugs: sticker shock [Editorial]. Ann Neurol. 2012;71:A5-6. [PMID: 22522488]
31. Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology. 2011;77:355-63. [PMID: 21775734]
32. Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2013;19:1074-83. [PMID: 23234810]
33. Correale J, Ysrraelit MC, Gaitán MI. Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. J Immunol. 2010;185:4948-58. [PMID: 20855882]
34. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72:234-40. [PMID: 22926855]
35. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010;68:193-203. [PMID: 20695012]
36. Soilu-Hänninen M, Aivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83:565-71. [PMID: 22362918]
37. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology. 2012;79:261-6. [PMID: 22700811]
38. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults W T, Kaufman DI, et al. A randomized, controlled trial of corti-costeroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581-8. [PMID: 1734247]
39. Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió I Torrenta L, Brieva L, et al. A randomized clinical trial of oral versus intravenous methylpredisolone for relapse of MS. Mult Scler. 2013. Epub ahead of print. [PMID: 24144876]
40. Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology. 2004;63:1079-80. [PMID: 15452302]
41. Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif. 2009;28:108-15. [PMID: 19521072]
42. Simsarian JP, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Devel Ther. 2011;5:381-9. [PMID: 21792296]
43. Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology. 2007;68:1614-7. [PMID: 17485649]
44. Rutschmann OT, McCrory DC, Matchar DB; Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines. Immunization and MS: a summary of published evidence and recommendations. Neurology. 2002;59:1837-43. [PMID: 12499473]
45. Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011;258:1197-206. [PMID: 21431896]